NexImmune, Inc.
NASDAQ:NEXI
0.221 (USD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 2.121 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 0 | 0.115 | 0.229 | 0.266 | 0.4 | 0.395 | 0.423 | 0.326 | 0.397 | 0.349 | 0.235 | 0.241 | 0.216 | 0.174 | 0 | 0 | 0 | 0 | 0 |
Gross Profit
| 0 | -0.115 | 1.892 | -0.266 | -0.4 | -0.395 | -0.423 | -0.326 | -0.397 | -0.349 | -0.235 | -0.241 | -0.216 | -0.174 | 0 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0 | 0 | 0.892 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 0.647 | 0.629 | 2.272 | 6.006 | 4.88 | 6.124 | 13.726 | 11.137 | 11.838 | 10.449 | 11.988 | 11.331 | 8.125 | 6.013 | 4.445 | 4.913 | 4.209 | 4.272 | 3.699 |
General & Administrative Expenses
| 2,082.494 | 2.013 | 2.405 | 3.99 | 2.904 | 3.701 | 3.522 | 3.72 | 4.088 | 4.605 | 3.545 | 4.159 | 4.038 | 4.058 | 2.606 | 2.752 | 2.565 | 2.088 | 1.469 |
Selling & Marketing Expenses
| -2,080.412 | -2,011.43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 2.082 | 2.013 | 2.405 | 3.99 | 2.904 | 3.701 | 3.522 | 3.72 | 4.088 | 4.605 | 3.545 | 4.159 | 4.038 | 4.058 | 2.606 | 2.752 | 2.565 | 2.088 | 1.469 |
Other Expenses
| 0.779 | 0.097 | -0.036 | -0.013 | -0.005 | -0.014 | 0.034 | -0.1 | -0.019 | -0.003 | -0.016 | -0.019 | -0.026 | -0.001 | 0.023 | 0.012 | 0.027 | 0.027 | 0.021 |
Operating Expenses
| 3,509.306 | 2.643 | 4.677 | 9.996 | 7.785 | 9.825 | 17.247 | 14.856 | 15.926 | 15.054 | 15.532 | 15.49 | 12.163 | 10.07 | 7.051 | 7.665 | 6.775 | 6.361 | 5.168 |
Operating Income
| -3.509 | -2.757 | -5.368 | -9.996 | -7.785 | -9.825 | -17.247 | -14.856 | -15.926 | -15.054 | -15.532 | -15.49 | -12.163 | -10.07 | -7.051 | -7.665 | -6.775 | -6.361 | -5.168 |
Operating Income Ratio
| 0 | 0 | -2.531 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 1.183 | -0.32 | -1.666 | -1.964 | 0.071 | 0.134 | 0.354 | 0.127 | 0.065 | 0.031 | 0.007 | 0.843 | -0.019 | 1.524 | -0.96 | -0.943 | -0.156 | 0.045 | 0.046 |
Income Before Tax
| -2.327 | -3.077 | -5.359 | -9.854 | -7.567 | -9.565 | -16.893 | -14.729 | -15.861 | -15.023 | -15.526 | -14.647 | -12.182 | -8.547 | -8.011 | -8.609 | -6.931 | -6.316 | -5.122 |
Income Before Tax Ratio
| 0 | 0 | -2.527 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| -0.075 | -2,757.581 | -0.045 | -0.266 | -0.223 | -260.332 | -0.577 | -0.127 | -0.065 | -0.031 | -0.016 | -0.018 | -0.026 | 0.903 | 0.962 | 0.572 | 0.21 | 0.028 | -0.325 |
Net Income
| -2.327 | -3.077 | -5.359 | -9.854 | -7.567 | 250.767 | -16.316 | -14.603 | -15.796 | -14.992 | -15.526 | -14.647 | -12.182 | -8.547 | -8.011 | -8.609 | -6.931 | -6.316 | -5.122 |
Net Income Ratio
| 0 | 0 | -2.527 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS
| -1.69 | -2.46 | -5.03 | -9.4 | -7.25 | 240.4 | -15.64 | -14.96 | -17.27 | -16.41 | -17 | -16.12 | -13.46 | -9.46 | -8.11 | -13.32 | -10.72 | -9.77 | -7.92 |
EPS Diluted
| -1.69 | -2.46 | -5.03 | -9.4 | -7.25 | 240.4 | -15.64 | -14.96 | -17.27 | -16.41 | -17 | -16.12 | -13.46 | -9.46 | -8.11 | -13.32 | -10.72 | -9.77 | -7.92 |
EBITDA
| -2.654 | -2.643 | -3.464 | -7.625 | -7.238 | -9.305 | -16.824 | -14.53 | -15.529 | -14.705 | -15.298 | -15.25 | -11.947 | -7.468 | -6.901 | -7.495 | -6.6 | -6.171 | -5.336 |
EBITDA Ratio
| 0 | 0 | -2.098 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |